← Leaderboards
Rocio Canals Alvarez
Glaxosmithkline Biologicals
$2,427,378
Attributed
$2,427,378
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $810K · FY2023–25$1M$750K$500K$250K$0
'23
'24
'25
Funding mix
By agency
NIH$2,427,378 · 1
By mechanism
R01$2,427,378 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Rising Stars on “Advanced Development”
- Kiran Datta · Leidos Biomedical Research, Inc.$277,585,346
- Katherine M Thibault · Battelle Memorial Institute$134,148,552
- Mari Ostendorf · University Of Washington$51,931,230
- Richard Smith · Medical Device Innovation Consortium$41,401,350
- Brian Zavertnik · Palantir Technologies, Inc.$33,059,912
- Cyrus Wadia · Activate Global, Inc.$31,489,493
Research focus
Advanced DevelopmentAffinityAfricaAnimal ModelAntibodiesAntigensAsiaBactericideBiologicalCause Of DeathCessation Of LifeClassificationClinical ResearchClinical TrialsCostCross Reacting Material 197Diarrheal DiseaseDoseEffectivenessEnteralEnteric InfectionExperimental StudyFever5 Year Old
Grant awards (3)
Development of Robust and Low-cost Vaccines Against Salmonella Paratyphi A$808,308
R01 · FY2025 · AI · contact PI
Development of Robust and Low-cost Vaccines Against Salmonella Paratyphi A$809,070
R01 · FY2024 · AI · contact PI
Development of Robust and Low-cost Vaccines Against Salmonella Paratyphi A$810,000
R01 · FY2023 · AI · contact PI